MedTrace Logo

Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

NCT00372385 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 334

Last updated 2014-07-23

Study results available
· View outcomes & findings →

Summary

Compare the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) with and without Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

Ribavirin

tablet

DRUG

Pegylated Interferon Alfa 2a

Solution for injection

DRUG

Placebo

tablet

DRUG

Telaprevir

tablet

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Vertex Pharmaceuticals Incorporated

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2008-05-31
Completion
2008-06-30

Countries

  • Austria
  • France
  • Germany
  • United Kingdom

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00372385 on ClinicalTrials.gov